Raven Biotechnologies, Inc., has entered into an agreement with Wyeth Pharmaceuticals to develop and commercialize selected MAbs from Raven’s portfolio of antibodies to a specified target. Under the terms of the agreement, Wyeth has the option to obtain an exclusive license to develop and commercialize therapies resulting from Raven’s designated antibodies. Terms of the agreement include an upfront payment, milestone payments and royalties based upon the net sales of products de...